The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis

Xijing Hospital250 enrolled

Overview

This study evaluates the safety and therapeutic effects of single-dose human umbilical cord blood mesenchymal stem cells (UC-MSCs) on the adult patients with moderate/severe Rheumatoid Arthritis accompany with anemia or/and Interstitial pulmonary disease. Half of participants will receive UC-MSCs and keep the present medication,while the other half will receive a placebo and keep the present medication.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

250

Conditions

Rheumatoid Arthritis

Interventions

UC-MSCsBIOLOGICAL

The UC-MSCs will be administrated by intravenous injection at the dose of 1×10\^6 cells/kg.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Fulfill 2010 ACR/ the European League Against Rheumatism (EULAR) classification criteria or the 1987 ACR classification criteria. 2. Age limits:18 to 70 years old. 3. Freely given informed consent. 4. Disease Activity Score (DAS) 28≥3.2或 Simple Disease Activity Index (SDAI)\>11.0或 Clinical Disease Activity Index (CDAI) \>10.0. 5. Hemoglobin \< 90 g/L and/or interstitial lung disease shown in high resolution CT. 6. Poor response to current treatment. The current treatment refers to receive the medicines (including Leflunomide, Methotrexate, Sulphasalazine, Hydroxychloroquine, Cyclosporine A,and Tacrolimus, alone or in combination ) for 3 months, and maintain the stable-dose of drugs for at least 1 month. 7. More than 3 months and a stable dose for at least 1 month are required if glucocorticoid is used. The dose of glucocorticoid is less than or equal to10mg/ day of prednisone. Exclusion Criteria: 1. Participants who received glucocorticoid therapy by intra-articular injection within 1 week. 2. Glucocorticoid that participants received is more than 10 mg/day of prednisone within 1 months. 3. Complication with other connective tissue disease (except for Sjogren syndrome) . 4. Participants with chronic and acute infection (bacteria, virus and parasite,etc.). 5. Participants with acute and chronic tuberculosis infection. 6. Malignant tumors or participants with a family history of malignant tumors. 7. Participants have a family history of allergic conditions. 8. Participants infected by Hepatitis B Virus(HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus （HIV）. 9. Participants suffer from central nervous system demyelinating disease or multiple sclerosis (MS) currently or in the past. 10. Participants received live vaccines with 3 months. 11. Drug abuse and alcoholism. 12. Participants with severe mental or neurological disorders that affect informed consent and/or the presentation or observer of adverse events. 13. Participants with pregnant or in breast-feeding, and patients who has a pregnancy plan within 1 year. 14. Participants received stem cell therapy in the past. 15. Participants received any biological agents within 3 months. 16. Anemia (such as anemia with dysplasia) and interstitial lung disease for other reasons. 17. Participants with cardiovascular and cerebrovascular damage, such as thrombosis. 18. Participants taking drugs that affect the test for blood and lung. 19. Participants taking any traditional Chinese medicine. 20. Participants taking immune modulators such as Transfer Factor, Thymosin and Intravenous Immunoglobulin (IVIG), and so on. 21. Other cases that participants are considered by investigator that they did not meet the requirements for enrollment.

Locations (1)

Xijing Hospital

Xi'an, Shaanxi, China

RECRUITING

Outcomes

Primary Outcomes

Improvement rate of blood routine hemoglobin (HGB) compared to baseline.

The HGB increases by 10g compared to the baseline is considered improvement.

Time frame: 24 weeks

Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline.

FVC increases by 0.5% and DLCO increases by 10% compared to baseline are considered improvement.

Time frame: 24 weeks

Secondary Outcomes

The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.

The patients achieves 20%, 50%, or 70% remission according to American College of Rheumatology (ACR) criteria.

Time frame: 12 weeks and 24 weeks

White blood cell count and platelet count improved compared to the baseline.

White blood cell count increases to the 3.5×10\^9/L and platelet count increases to 80×10\^ 9.

Time frame: 12 weeks and 24 weeks

Improvement rate of blood routine hemoglobin (HGB) compared to baseline.

The HGB increases by 10 g compared to the baseline is considered improvement.

Time frame: 12 weeks

Improvement rate of forced vital capacity (FVC) and/or carbon monoxide

FVC increases by 0.5% and DLCO increases by 10% compared to baseline

Time frame: 12 weeks

Image improvement of lung on high resolution CT.

The area change of image of lung.

Time frame: 24 weeks

Central Contacts

Ping Zhu, Doctor

CONTACT

86-29-84773951 zhuping@fmmu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.